Genmab to attend Kempen & Co Life Sciences

Copenhagen, Denmark; March 11, 2010- Genmab A/S (OMX: GEN) announced today its
President, R&D and Chief Scientific Officer, Prof. Jan van de Winkel, Ph.D.
will attend the Kempen & Co. Life Sciences Conference on March 23 in Brussels,
Belgium. 

About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer. 
Genmab's world class discovery and development teams are using cutting-edge
technology to create and develop products to address unmet medical needs.  Our
primary goal is to improve the lives of patients who are in urgent need of new
treatment options.  For more information on Genmab's products and technology,
visit www.genmab.com. 

This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product
discovery and development, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our products, our
inability to manage growth, the competitive environment in relation to our
business area and markets, our inability to attract and retain suitably
qualified personnel, the unenforceability or lack of protection of our patents
and proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and other
factors. For a further discussion of these risks, please refer to the section
“Risk Management” in Genmab's Annual Report, which is available on
www.genmab.com.  Genmab does not undertake any obligation to update or revise
forward looking statements in this press release nor to confirm such statements
in relation to actual results, unless required by law. 

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax-EGFr™;
HuMax-IL8™; HuMax-TAC™; HuMax-HepC™; HuMax-CD38™; HuMax-CD32b™; HuMax-TF™;
HuMax-Her2™; HuMax-VEGF™ and UniBody® are all trademarks of Genmab A/S.
Arzerra™ is a trademark of GlaxoSmithKline. 

Contact:		Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

###

Investor News no. 2/2010